Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 18/20 | 0.58 |
| ▸ | MAPT | P10636 | 15/20 | 0.58 |
| ▸ | TP53 | P04637 | 7/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814088 | 0.90 | GAA (0.49) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2814905 | 0.88 | GAA (0.51) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2810374 | 0.86 | GAA (0.66) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2814190 | 0.83 | GAA (0.50) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2293280 | 0.81 | GAA (0.47) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2292728 | 0.81 | GAA (0.48) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL13885431 | 0.80 | GAA (0.43) | GAAMAPTTP53THRBL3MBTL1 | |
| SCHEMBL2288177 | 0.80 | GAA (0.50) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2293580 | 0.79 | GAA (0.55) | GAAMAPTTP53MAPK1KMT2A | |
| SCHEMBL2808371 | 0.79 | GAA (0.43) | GAAMAPTTP53MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | claimed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | claimed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2195322-A1 | IMIDAZOÝ1,2-A¨PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | Merck Patent GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009049731-A1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049731-A1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | TYMS, CCNT1, INSR | GAA 1202/4885MAPT 3889/4885TP53 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.